SODIUM DESOXYCHOLATE

Molecular Excipient

Mwt. LogP HBD HBA PSA RB CSP3
392.0 3.1 2 4 81.0 4 0.96
CAS
302954
UNII
436LS6U35Y
SYNONYMS
ZINC ID(s)
Availability
Present in 66 ZINC catalogs

Known Active Genes

This compound has been observed to have activity at 10μM or less against the following gene(s).
Name Description Classification
SLC10A2 Ileal sodium/bile acid cotransporter Unclassified / Unclassified
GPBAR1 G-protein coupled bile acid receptor 1 Membrane Receptor / Gpcr-A

Clinical Trials

This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
Code Date Title Phase Status
NCT01945281 2014-01-01 Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064) Phase 2 Recruiting
NCT00815516 2012-06-01 Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis Phase 3 Terminated
NCT01310738 2011-02-01 Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil Phase 4 Terminated
NCT00696969 2008-06-01 Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Phase 3 Completed
NCT00628719 2008-02-01 Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis Phase 3 Completed
NCT01032187 2007-10-01 Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Phase 4 Completed
NCT00523965 2007-09-01 Combination Therapy in Indian Visceral Leishmaniasis Phase 3 Completed
NCT00422188 2007-01-01 ATX-101 (Sodium Deoxycholate for Injection) for the Treatment of Superficial Lipomas Phase 1 Completed
NCT00361517 2006-06-01 To Determine Whether Galactomannan Test Will Help to Detect Fungal Infections Early and Hence Start Treatment Early Phase 3 Terminated
NCT00003031 1997-06-01 Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis Phase 3 Completed
NCT00002742 1996-01-01 Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer Phase 3 Completed

(Browse) Purchasable Analogs in ZINC

Dosages

Route Formulation Per Unit Dose
Iv(infusion) Injection
Iv(infusion) Powder, For Injection Solution 4.1%

More Information

Usage Over Time

Comments